About Chosen Diagnostics
Chosen Diagnostics is a Healthcare company based in New Orleans (United States) founded in 2011. Developing a novel MDx kit to diagnose a severe bowel disorder in premature infants. Its focus areas include Life Sciences, Gastroenterology, In Vitro Diagnostic Tests and Bowel Disease. Its legal entity is Chosen Diagnostics Inc. Its competitors include GenScript, BioLife Solutions and Fluent BioSciences; 2 of its 3 listed competitors have raised funding.
Company details
Chosen Diagnostics was founded in 2011 in New Orleans, United States, within the molecular diagnostics sector. Neonatal DDx, a diagnostic kit for necrotizing enterocolitis in premature infants, has been developed by the company. Human trials involving 49 patients have been completed, achieving 93 percent accuracy in disease identification. Operations focus on advancing diagnostic tools for neonatal bowel disorders.
- Headquarters New Orleans, United States
- SectorsHealthcare
- Email••••••••
- Website chosendiagnostics.com
- Legal Name Chosen Diagnostics Inc
- Latest Funding Round$224.76K (USD), Grant
Jun 2020
- InvestorsHHS
& 2 more
Funding Insights of Chosen Diagnostics
- Total Rounds 4
- Last Round Grant — $224,758
- First Round $25,000
(Nov 2018)
- Investors Count 3
All 4 funding rounds of Chosen Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $224,758 | Grant | – | – | |
| May 2020 | $224,758 | Grant | – | – | |
| Sep 2019 | $2.35M | Grant | – | – | |
| Nov 2018 | $25,000 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Chosen Diagnostics
Chosen Diagnostics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, America’s Seed Fund and New Orleans BioInnovation Center.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
A center dedicated to supporting biotech innovators in Louisiana. | neworleansbio.com | New Orleans, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Chosen Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Chosen Diagnostics
3 dated milestones of Chosen Diagnostics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Chosen Diagnostics is founded.
- Funding First funding round of $25K.
- Funding Latest funding round, Grant, of $225K.
Competitors of Chosen Diagnostics
Chosen Diagnostics has 3 listed competitors in our database, 2 of them funded. They include GenScript, BioLife Solutions and Fluent BioSciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| biolifesolutions.com | 1987 | Bothell, United States | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | ||
| fluentbio.com | 2018 | Watertown, United States | $19M | Proprietary reagents for single-cell genetic analysis are developed. |
Detailed competitors of Chosen Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Chosen Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chosen Diagnostics
Complete news archive for Chosen Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chosen Diagnostics
Chosen Diagnostics was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Chosen Diagnostics is headquartered in New Orleans, United States. It is registered at New Orleans, Louisiana, United States.
Chosen Diagnostics was founded in 2011 in New Orleans, United States, within the molecular diagnostics sector. Neonatal DDx, a diagnostic kit for necrotizing enterocolitis in premature infants, has been developed by the company. Human trials involving 49 patients have been completed, achieving 93 percent accuracy in disease identification. Operations focus on advancing diagnostic tools for neonatal bowel disorders.
Chosen Diagnostics's top competitors include BioLife Solutions, GenScript and Fluent BioSciences.
Chosen Diagnostics has 3 investors. Key investors include HHS, America’s Seed Fund, and New Orleans BioInnovation Center.
Chosen Diagnostics operates through Chosen Diagnostics Inc.